First biological evaluation of developed 3-benzyloxyfluorenes as novel class of MDR modulators

European Journal of Medicinal Chemistry

Volumn 45, Issue 6, 2010, Pages 2683-2688

  Krug, Martin ^a   Voigt, Burkhardt ^a   Baumert, Christiane ^a   Lüpken, Ralf ^a   Molnár, Joséf ^b   Hilgeroth, Andreas ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

ABCB1 inhibitor; Binding site; Efflux pump; Lipophilicity calculation; MDR modulator

Indexed keywords

1 ACETYL 3 (3 CHLOROBENZYLOXY) 4 (3 CHLOROPHENYL) 1,4 DIHYDROPYRIDINE; 1 ACETYL 3 (3 CHLOROBENZYLOXY) 4 (4 CHLOROPHENYL) 1,4 DIHYDROPYRIDINE; 1 ACETYL 3 (3 CHLOROBENZYLOXY) 4 PHENYL 1,4 DIHYDROPYRIDINE; 1 ACETYL 3 (4 CHLOROBENZYLOXY) 4 (3 CHLOROPHENYL) 1,4 DIHYDROPYRIDINE; 1 ACETYL 3 (4 CHLOROBENZYLOXY) 4 (4 CHLOROPHENYL) 1,4 DIHYDROPYRIDINE; 1 ACETYL 3 (4 CHLOROBENZYLOXY) 4 PHENYL 1,4 DIHYDRO PYRIDINE; 1 ACETYL 3 BENZYLOXY 4 (3 CHLOROPHENYL) 1,4 DIHYDROPYRIDINE; 1 ACETYL 3 BENZYLOXY 4 (4 CHLOROPHENYL) 1,4 DIHYDROPYRIDINE; 1 ACETYL 3 BENZYLOXY 4 PHENYL 1,4 DIHYDROPYRIDINE; 3 (3 CHLOROBENZYLOXY) 4 (3 CHLOROPHENYL)[1]BENZOFURO[2,3 B]PYRIDINE 6 OL; 3 (3 CHLOROBENZYLOXY) 4 (4 CHLOROPHENYL)[1]BENZOFURO[2,3 B]PYRIDINE 6 OL; 3 (3 CHLOROBENZYLOXY) 4 PHENYL[1]BENZOFURO[2,3 B]PYRIDINE 6 OL; 3 (3 CHLOROBENZYLOXY) 4 PHENYLPYRIDINE; 3 (3 CHLOROBENZYLOXY)PYRIDINE; 3 (4 CHLOROBENZYLOXY) 4 (3 CHLOROPHENYL)[1]BENZOFURO[2,3 B]PYRIDINE 6 OL; 3 (4 CHLOROBENZYLOXY) 4 (4 CHLOROPHENYL)[1]BENZOFURO[2,3 B]PYRIDINE 6 OL; 3 (4 CHLOROBENZYLOXY) 4 PHENYL[1]BENZOFURO[2,3 B]PYRIDINE 6 OL; 3 (4 CHLOROBENZYLOXY) 4 PHENYLPYRIDINE; 3 (4 CHLOROBENZYLOXY)PYRIDINE; 3 BENZYLOXY 4 (3 CHLOROPHENYL)[1]BENZOFURO[2,3 B]PYRIDINE 6 OL; 3 BENZYLOXY 4 (3 CHLOROPHENYL)PYRIDINE; 3 BENZYLOXY 4 (4 CHLOROPHENYL)[1]BENZOFURO[2,3 B]PYRIDINE 6 OL; 3 BENZYLOXY 4 (4 CHLOROPHENYL)PYRIDINE; 3 BENZYLOXY 4 PHENYL[1]BENZOFURO[2,3 B]PYRIDINE 6 OL; 3 BENZYLOXY 4 PHENYLPYRIDINE; 3 BENZYLOXYPYRIDINE; FLUORENE DERIVATIVE; IMMUNOMODULATING AGENT; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; CANCER THERAPY; DRUG ACTIVITY; DRUG SCREENING; IMMUNOMODULATION; LIPOPHILICITY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL LINE, TUMOR; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE; FLUORENES; HYDROPHOBICITY; MICE; NEOPLASMS; P-GLYCOPROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77950866366     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.02.024     Document Type: Article

References (14)

1. Sharom F.J. Pharmacogenomics 9 (2008) 105-127
2. Gottesmann M.M., and Ling V. FEBS Lett. 580 (2006) 998-1009
3. Schinkel A.H., and Jonker J.W. Adv. Drug Deliv. Rev. 55 (2003) 3-29
4. Sheps J.A., and Ling V. Eur. J. Physiol. 453 (2007) 545-553
5. Rees D.C., Johnson E., and Lewinson O. Nature Rev. Mol. Cell Biol. 10 (2009) 218-227
6. Aller G.St., Yu J., Ward A., Weng Y., Chittaboina S., Zhuo R., Harrell P.M., Trinh Y.T., and Urbatsch I.L. Science 323 (2009) 1718-1722
7. Baumert C., and Hilgeroth A. Anti-Cancer Agents Med. Chem. 9 (2009) 415-436
8. Kozikowski A.P., Araldi G.L., and Ball R.G. J. Org. Chem. 62 (1997) 503-509
9. Hilgeroth A., Brachwitz K., and Baumeister U. Heterocycles 55 (2001) 661-669
10. Lee J., Paull K., Alvarez M., Hose C., Monks A., Grever M., Fojo A., and Bates S. Mol. Pharm. 46 (1994) 627-638
11. Wiese M., and Pajeva I. Curr. Med. Chem. 8 (2001) 685-713
12. http://www.vcclab.org/lab/alogps/.
13. Richter M., Molnár J., and Hilgeroth A. J. Med. Chem. 49 (2006) 2838-2840
14. Wollmann J., Richter M., Molnár J., and Hilgeroth A. ChemBioChem 6 (2005) 1353-1356